argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET

Company Participants

Beth DelGiacco - VP and Global Head, Corporate Communications and IR

Tim Van Hauwermeiren - CEO

Karl Gubitz - CFO

Karen Massey - COO

Conference Call Participants

Yatin Suneja - Guggenheim Partners

Tazeen Ahmad - Bank of America

Derek Archila - Wells Fargo

Thomas Smith - Leerink Partners

James Gordon - JPMorgan

Amy Li - Jefferies

Danielle Brill - Raymond James

Yaron Werber - TD Cowen

Myles Minter - William Blair

Joel Beatty - Baird

Alex Thompson - Stiefel

Allison Bratzel - Piper Sandler

Vikram Purohit - Morgan Stanley

Manos Mastorakis - Deutsche Bank

Douglas Tsao - H.C. Wainwright

Joon Lee - Truist Securities

Suzanne van Voorthuizen - VLK

Samantha Semenkow - Citi

Rajan Sharma - Goldman Sachs

Charles Pitman - Barclays

Operator

Good morning. My name is Ralph, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions]

Thank you. I'd like to introduce Beth DelGiacco, Vice President, Global Head of Corporate Communications and Investor Relations. You may now begin your conference.

Beth DelGiacco

Thank you, operator. A press release was issued earlier today with our third quarter 2023 financial results and business update. This can be found on our website, along with the presentation for today's webcast.

Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones. Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to update statements regarding the future or to conform those statements in relation to actual results unless required by law.

I'm joined on the call today by Tim Van Hauwermeiren, Chief Executive Officer; Karl Gubitz, Chief Financial Officer; and Karen Massey, Chief Operating Officer.

I'll now turn the call to Tim.

Tim Van Hauwermeiren

Thank you, Beth, and welcome everyone.

Slides 3. It is incredible to see what argenx team has accomplished this year meticulously delivering on the ambitious plan they laid out in January. We are reaching more and more gMG patients around the world and brought a subcutaneous product to the markets only 18 months after the IV launch. We reported stelas CIDP data and now have a path forward to approval next year.